(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Andrew J. MacDougall to the board of directors, effective immediately, in order to satisfy the statutory requirement for resident Canadians to comprise at least 25% of the board […]
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has applied to the Toronto Stock Exchange to extend the expiry date of the 2009 Warrants (as defined below) by six months, from March 7, 2013 at 5:00 p.m. […]
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced that on Friday, February 8, 2013 John A. Rogers has voluntarily resigned from Helix’s board of directors. About Helix BioPharma Corp. Helix BioPharma Corp. is a biopharmaceutical company specializing in the field […]
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced today the completion of the previously announced sale of its Rivex Pharma division to Pharmascience Inc. (“Pharmascience”) for gross cash proceeds of $8.5 million, subject to adjustment (the “Rivex Transaction”). The […]
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces that its Annual General and Special Meeting (the “Shareholder Meeting”) was held today as scheduled. At the Shareholder Meeting, Helix received approval of 100% of the votes cast by shareholders present, […]